Clinical trials: Chronic Nephropathy
Renal Insufficiency, Chronic, Heart Failure
Clinical Validation Through Analytical Study With Urine Samples to Compare the Effectiveness and Security of an Intelligent Device
The objectives of the Clinical Validation Through Analytical Study With Urine Samples to Compare the Effectiveness and Security of an Intelligent Device are: 1.To evaluate the performance of S-There Device in comparison to the…
- Conditions
- Renal Insufficiency, Chronic, Heart Failure, Diabete Mellitus, Diabetes; Nephropathy (Manifestation)
- Trial name
- STSD-2019-001 (NCT03965975)
- Testing
- Lab Gold Standard, S-There
- Where
- Spain
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- S-There Technologies SL
Anemia, Iron-Deficiency, Kidney Failure, Chronic
DRIVE Trial (Dialysis Patients' Response to Intravenous [IV] Iron With Elevated Ferritin)
This study explores the safety and efficacy of intravenous iron therapy in anemic hemodialysis patients treated with epoetin alfa, who have higher serum ferritin levels, but low to normal transferrin saturation.
- Conditions
- Anemia, Iron-Deficiency, Kidney Failure, Chronic, Hemodialysis
- Trial name
- DRIVE (NCT00224081)
- Testing
- Sodium ferric gluconate,
- Where
- 29 sites in United States
- Volunteers
- 134 people
- Sponsor
- Watson Pharmaceuticals
Chronic Kidney Disease Stage 5
Quality of Life and Depression in Dialysis Patients
The aim of this study is to evaluate quality of life (QOL) and depression in peritoneal dialysis patients compare to hemodialysis patients and assess hydration effect on QOL and depression over time.
- Trial name
- QOLD (NCT01668628)
- Where
- South Korea
- Volunteers
- 1,068 people
- Sponsor
- Fresenius Medical Care Korea
Anemia
A Study of Mircera for the Maintenance Treatment of Anemia in Dialysis Patients
This 2 arm study will compare the efficacy and safety of Mircera and darbepoetin alfa, administered at extended dosing intervals, in the maintenance treatment of anemia in patients with chronic kidney disease (CKD) who are on…
- Trial name
- NCT00394953
- Testing
- Darbepoetin alfa, methoxy polyethylene glycol-epoetin beta [Mircera]
- Where
- 88 sites in Australia, Austria and 12 more
- Volunteers
- 490 people
- Sponsor
- Hoffmann-La Roche
Heart Failure, Chronic Kidney Disease
Dapagliflozin Post Marketing Surveillance in HF and CKD
This is an observational, non-interventional, single-arm multicenter study. The objectives of this study are to assess safety and effectiveness of Forxiga in a real world setting in patients who are prescribed with the study drug…
- Trial name
- NCT05134701
- Where
- 26 sites in South Korea
- Volunteers
- 815 people
- Sponsor
- AstraZeneca
Diabetic Nephropathy, Chronic Kidney Disease
The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors
The study objective was to evaluate the safety of paricalcitol capsules and the efficacy of paricalcitol capsules for albuminuria reduction in patients with Chronic Kidney Disease (CKD) who have Type 2 diabetic nephropathy and…
- Trial name
- VITAL (NCT00421733)
- Testing
- Zemplar (paricalcitol ) capsules, Zemplar (paricalcitol) capsules
- Where
- 72 sites in United States, Germany and 8 more
- Volunteers
- 281 people
- Sponsor
- Abbott
Chronic Kidney Diseases
Medico-economic Evaluation of a Telemedicine System for the Management of Chronic Renal Failure
The main objective of this study is to demonstrate the efficiency ( cost-effectiveness ) of a telemedicine system : eNephro Application , compared with traditional care in the management of chronic renal failure in different…
- Trial name
- eNephro (NCT02082093)
- Testing
- Telemedicine System
- Where
- 8 sites in France
- Volunteers
- 635 people
- Sponsor
- Pharmagest Interactive
High Cardiovascular Risk, Hypertension
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3)
The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.
- Trial name
- KARDIA-3 (NCT06272487)
- Testing
- Zilebesiran
- Where
- 195 sites in United States, Australia and 4 more
- Volunteers
- 375 people
- Sponsor
- Alnylam Pharmaceuticals
Pure Red-Cell Aplasia, Chronic Kidney Failure
Surveillance Study to Estimate the Incidence of Pure Red Blood Cell Aplasia Among Patients With Chronic Kidney Failure
The purpose of this study is to estimate the incidence rate of pure red cell aplasia (PRCA; aplastic anemia) mediated by erythropoietin (EPO) antibodies in patients who are receiving subcutaneous (s.c.) epoetin alfa (polysorbate…
- Trial name
- PRIMS (NCT00391287)
- Where
- 387 sites in Australia, Belgium and 13 more
- Volunteers
- 15,334 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
End-stage Renal Disease, Renal Failure Chronic Requiring Hemodialysis
Study to Evaluate Daptomycin Given During Dialysis and After Dialysis
The purpose of this study is to determine whether daptomycin at a higher dose given during the last 30 minutes of a dialysis session is equal to a lower dose of daptomycin given after a dialysis session.
- Trial name
- NCT00882557
- Testing
- daptomycin
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Autosomal Dominant Polycystic Kidney Disease
Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease
This study will assess whether everolimus (RAD001) is effective in preventing cyst and kidney expansion as well as worsening of renal function in patients with ADPKD and whether the application of 5 mg/day everolimus as…
- Trial name
- NCT00414440
- Testing
- Everolimus
- Where
- 24 sites in Austria, France and 1 more
- Volunteers
- 431 people
- Sponsor
- Novartis Pharmaceuticals
Renal Insufficiency, Chronic
Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)
The objective of this study is to determine whether paricalcitol is safe and effective compared to placebo in reducing elevated serum PTH levels in patients with chronic kidney disease.
- Trial name
- NCT00048438
- Testing
- paricalcitol
- Where
- 18 sites in United States, Poland
- Volunteers
- 68 people
- Sponsor
- Abbott
Anemia, Renal Insufficiency, Chronic
A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects
The purpose of this study is to evaluate the efficacy and safety of molidustat in non-dialysis subjects previously treated with Erythropoiesis-Stimulating Agents (ESAs)
- Trial name
- MIYABI ND-M (NCT03350347)
- Testing
- Molidustat (BAY85-3934), Darbepoetin alfa
- Where
- 59 sites in Japan
- Volunteers
- 164 people
- Sponsor
- Bayer
Kidney Transplant, Kidney Failure
Hypothermic Machine Perfusion With Omnisol of Deceased Donor Kidneys Prior to Transplantation
Insufficient availability of organs from brain dead (DBD) and living donors has necessitated increased use of less than optimal organs from donation after cardiac death (DCD) or from extended criteria donors.
- Conditions
- Kidney Transplant, Kidney Failure, Renal and Urinary Tract Therapeutic Procedures, End Stage Renal Disease (ESRD)
- Trial name
- NEWHOPE (NCT07792317)
- Testing
- Omnisol organ preservation solution
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Vivalyx GmbH
Chronic Kidney Disease
Study of an Autologous Neo-Kidney Augment in Patients With Chronic Kidney Disease
The primary purpose of this study is to assess the safety and optimal delivery of the Neo-Kidney Augment (NKA) when implanted at one site in a recipient kidney.
- Trial name
- NCT01846715
- Testing
- Implantation of SRC
- Where
- 2 sites in Sweden
- Volunteers
- 6 people
- Sponsor
- Tengion
Chronic Kidney Disease
EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)
The primary aim of the study is to investigate the effect of empagliflozin on kidney disease progression or cardiovascular death versus placebo on top of standard of care in patients with pre-existing chronic kidney disease.
- Trial name
- NCT03594110
- Testing
- Empagliflozin
- Where
- 240 sites in United States, Canada and 6 more
- Volunteers
- 6,609 people
- Sponsor
- Boehringer Ingelheim
Kidney Disease, Chronic
A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease
This study is open to adults with chronic kidney disease. People with and without type 2 diabetes can take part in this study. The purpose of this study is to find out whether a medicine called BI 690517 improves kidney function…
- Trial name
- NCT05182840
- Testing
- BI 690517, Empagliflozin
- Where
- 203 sites in United States, Argentina and 27 more
- Volunteers
- 714 people
- Sponsor
- Boehringer Ingelheim
Chronic Glomerulonephritis, Diabetic Nephropathy
Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic Nephropathy
The treatment period was 16 weeks, the initial dose, 5 mg, was unforcedly titrated to 10 mg, 20 mg and 40 mg after confirming tolerance at weeks 4, 8 and 12.
- Trial name
- NCT00914524
- Testing
- olmesartan medoxomil
- Where
- Japan
- Volunteers
- 49 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Chronic Kidney Failure
Reduction of Heparin Dose in Dialysis With Evodial System
The current clinical study aims at defining an index of Anti Xa, which is the marker to evaluate the activity of heparin, at the end of the dialysis treatment and so showing the possibility to decrease heparin doses during…
- Trial name
- RHODES (NCT00781690)
- Testing
- Evodial hemodialysers and Evodia blood lines
- Where
- 7 sites in France, Germany and 2 more
- Volunteers
- 53 people
- Sponsor
- Vantive Health LLC
Type 2 Diabetes, Chronic Kidney Disease
A Study Comparing Dulaglutide With Insulin Glargine on Glycemic Control in Participants With Type 2 Diabetes (T2D) and Moderate or Severe Chronic Kidney Disease (CKD)
The purpose of this study is to determine the glycemic efficacy and safety of dulaglutide compared to insulin glargine in the treatment of participants with type 2 diabetes and moderate or severe chronic kidney disease.
- Trial name
- AWARD-7 (NCT01621178)
- Testing
- Dulaglutide, Insulin glargine, Insulin lispro
- Where
- 89 sites in United States, Brazil and 7 more
- Volunteers
- 577 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.